Aastrom reshuffles top posts
This article was originally published in Clinica
Cell therapy specialist Aastrom Biosciences will be making several personnel changes over the next few months in a bid to strengthen and expand its senior executive team. George Dunbar, current CEO, president, chief financial officer and a director of Aastrom, will transition out of his day-to-day management responsibilities and is expected to become chairman immediately after the company's annual shareholder meeting, scheduled for December 14. Board director and audit committee chairman Timothy Mayleben will succeed Mr Dunbar as CEO, president and CFO. Nelson Sims, the current chairman of the board, will take on the role of lead director, and assume Mr Mayleben's responsibilities as chair of the audit committee. Ann Arbor, Michigan-based Aastrom is developing autologous adult stem cell treatments for severe chronic cardiovascular diseases.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.